Clinical Trial Update: Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Folate Receptor Alpha Dendritic Cells (FRαDCs) vs placebo for stage III/IV ovarian, fallopian tube, or primary peritoneal cancer; curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Folate Receptor Alpha Dendritic Cells (FRαDCs)

Snippet

Sponsor: Mayo Clinic | Conditions: Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Status: RECRUITING